The present invention is directed to substituted aryl cycloalkanoyl
derivatives, compositions containing these derivatives, and methods of
their use for the prevention and treatment of conditions ameliorated by
monoamine reuptake including, inter alia, vasomotor symptoms (VMS),
sexual dysfunction, gastrointestinal and genitourinary disorders, chronic
fatigue syndrome, fibromylagia syndrome, nervous system disorders, and
combinations thereof, particularly those conditions selected from the
group consisting of major depressive disorder, vasomotor symptoms, stress
and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy,
and combinations thereof.
